Immutep (ASX:IMM) The TACTI-004 Phase III clinical trial aimed to evaluate the efficacy of eftiradimod alfa (“efti”), a leading immunotherapy candidate, in the first-line treatment of metastatic non-small cell lung cancer (NSCLC). announced the start of.

Efti is used in combination with Merck’s Keytruda (pembrolizumab) and chemotherapy. This will be compared to standard treatment with Keytruda chemotherapy (and a placebo).

This randomized, double-blind study will enroll approximately 750 patients with metastatic NSCLC and will be conducted at more than 150 clinical sites in more than 25 countries.

The trial will measure two primary endpoints: progression-free survival and overall survival.

“This…is an important step toward establishing a new standard of care for patients with metastatic NSCLC,” said Mark Voigt, CEO of Immutep. “Based on this, we believe it has the potential to bring about meaningful change.” We are impacting the lives of cancer patients and look forward to enrolling the first patient in this important study during the first quarter of 2025. ”

The stock closed 1.49% higher at 34 cents yesterday.